Obermatt
See Similar Stocks →

Day One Biopharmaceuticals

NSQ:DAWN · US23954D1090
BiotechnologySmall

360

39
Medium confidence — indicative
Profit price87
Owner Earnings Yield1
Dividend Yield1
Price/Sales52
EV / Gross Profit41
Price/Book25
Return on Capital63
Cash Return on Capital61
Return on Equity65
EBIT Margin28
Gross Profitability73
Accruals91
Owner Earnings Margin55
Sales growth73
Profit Growth5
Long-Term EPS Growth88
Reinvestment43
Price momentum86
Debt load84
Refinancing67
Debt Payback1
Liquidity16
Analyst ratings1
Opinion Changes50
Price Target Upside6
Market mood56
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Day One Biopharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePrivate Company
ExchangeNASDAQGS
Founded2018
Employees212
Websitedayonebio.com
ISINUS23954D1090
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsHealth DiagnosticsOncologyCentral Nervous SystemBiopharmaBiotechnologyHealth CareMedicalPharmaceutical

Description

Day One Biopharmaceuticals, Inc. (Day One), a biopharmaceutical company, develops and commercializes targeted therapies for people of all ages with life-threatening diseases. The company’s first commercial product, tovorafenib, is an oral, brain-pen…

Analysis

Middle-of-the-road

Day One Biopharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
52
—
—
—
Price/Earnings
100
—
—
—
Price/Book
25
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
65
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Day One Biopharmaceuticals with its peers
Xoma Royalty
NMQ:XOMA
40
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ArriVent BioPharma
NMQ:AVBP
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Palvella Therapeutics
NAQ:PVLA
100
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nuvalent
NSQ:NUVL
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Arcellx
NSQ:ACLX
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →